raloxifene hydrochloride has been researched along with Hyperplasia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bevers, TB | 1 |
| Braga, S; Cannata-Andía, JB; Carrillo-López, N; Fernández-Coto, T; López-Hernández, F; Lopez-Novoa, JM; Naves-Díaz, M; Rodríguez-Rodríguez, A | 1 |
| Clarfeld, RB; Costantino, JP; Grant, MD; McCaskill-Stevens, W; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
| Belli, AK; Buckley, JM; Coopey, SB; Gadd, MA; Garber, JE; Guidi, AJ; Hughes, KS; Kim, EM; Mazzola, E; Parmigiani, G; Polubriaginof, F; Roche, CA; Sharko, J; Smith, BL; Specht, MC | 1 |
| Chen, Y; Lin, GP; Tan, Z; Wang, TH; Xiang, QL | 1 |
| Gaynor, JS; Harken, AH; Miller, SA; Monnet, E; Selzman, CH; Turner, AS | 1 |
1 review(s) available for raloxifene hydrochloride and Hyperplasia
| Article | Year |
|---|---|
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemoprevention; Clinical Trials as Topic; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hyperplasia; Incidence; Multicenter Studies as Topic; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2010 |
5 other study(ies) available for raloxifene hydrochloride and Hyperplasia
| Article | Year |
|---|---|
Breast cancer risk reduction therapy: the low-hanging fruit.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Hyperplasia; Nitriles; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2015 |
Differential effects of 17beta-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency.
Topics: Animals; Atrophy; Bone Density Conservation Agents; Calcitriol; Calcium; Cholesterol; Chronic Disease; Estradiol; Estrogens; Female; Hyperplasia; Kidney Diseases; Mammary Glands, Animal; Organ Size; Parathyroid Hormone; Phosphorus; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tibia; Uterus | 2010 |
The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoprevention; Female; Humans; Hyperplasia; Mammary Glands, Human; Middle Aged; Precancerous Conditions; Raloxifene Hydrochloride; Tamoxifen | 2012 |
Effects of selective estrogen receptor modulator raloxifene plus 17-beta estradiol in aorta and mammary gland of female experimental atherosclerosis rabbits and possible involvement of ERK signal transduction pathway.
Topics: Animals; Aorta; Atherosclerosis; Blotting, Western; Drug Interactions; Estradiol; Extracellular Signal-Regulated MAP Kinases; Female; Hyperplasia; Lipids; Mammary Glands, Animal; Muscle, Smooth, Vascular; Rabbits; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Signal Transduction; Tetrazolium Salts; Thiazoles; Thymidine | 2006 |
Inhibition of intimal hyperplasia using the selective estrogen receptor modulator raloxifene.
Topics: Animals; Aorta; Arteriosclerosis; Bone Density; Cholesterol; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Female; Hyperplasia; Lipids; Ovariectomy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sheep; Triglycerides; Tunica Intima | 2002 |